𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma

✍ Scribed by Jordan Berlin; A. Christie King; Kendra Tutsch; John W. Findlay; Peter Kohler; Mary Collier; Neil J. Clendeninn; George Wilding

Publisher
Springer US
Year
1994
Tongue
English
Weight
447 KB
Volume
12
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; FrΓ©dΓ©ric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

Phase II trial of Didemnin B in patients
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma
✍ Robert Motzer; Howard Scher; Dean Bajorin; Cora Sternberg; George J. Bosl πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 115 KB

Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5070) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell

Interferon in combination with vinblasti
Interferon in combination with vinblastine in advanced malignant melanoma. A phase I–II study
✍ Stein Gundersen; A. Flokkmann πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 288 KB πŸ‘ 2 views

Nineteen patients with advanced malignant melanoma were treated with a combination of recombinant alfa-interferon (a-IFN) and vinblastine (VBL). The a-IFN was administered subcutaneously daily at an initial dose of 3 X lo6 IU escalating to a maximal dose of 9 X lo6 U daily for the first 10 weeks fol